Compare BridgeBio Pharma Inc (BBIO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Plby Group Inc — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while Plby Group Inc trades at $1.17 (market cap $136.40M). The key difference: BridgeBio Pharma Inc is far larger — about 120.7× Plby Group Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | PLBY | |
|---|---|---|
Market Cap | $16.46B | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $2.71 |
52-Week Low | $44.81 | $1.14 |
Enterprise Value | $18.02B | $284.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
PLBY trades at $1.17, up 0.86% today, but remains in a bearish technical trend. The company reported Q1 2026 revenue of $30.2 million with a narrowed net loss of $4.0 million, showing operational improvement. Recent news includes inclusion in Russell indexes and a major share repurchase. Despite negative ROE and high debt, analyst sentiment is positive with 75% buy ratings.
The outlook hinges on continued EBITDA growth and debt management. Opportunities include brand licensing momentum and cost controls. Key risks are persistent net losses, high leverage, and competitive pressures. Investors should weigh analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
